BIO Form 4: Rajat Mehta Receives 7,307 RSUs with Four-Year Vesting

Rhea-AI Filing Summary

Rajat Mehta, Executive Vice President, Global Commercial Operations at Bio-Rad Laboratories, Inc. (BIO), reported grants of restricted stock units on 09/05/2025. The Form 4 shows two awards: 1,827 RSUs and 5,480 RSUs, each representing the contingent right to one share of Bio-Rad Class A common stock. Both grants have a $0 per-unit reported conversion price and are held directly by the reporting person. The 1,827 RSUs vest in four equal annual installments beginning on the first anniversary of the grant date; the 5,480 RSUs vest over four years at 25% per year on each annual anniversary. The filing is signed 09/09/2025.

Positive

• Long-term alignment: Grants vest over four years, encouraging retention and alignment with shareholder interests
• Direct ownership: RSUs are held directly by the reporting person, making the executive a reported beneficial owner

Negative

• Potential dilution: 7,307 RSUs will convert into shares upon settlement, increasing outstanding shares
• No disclosed performance conditions: Awards appear to be time-based only, not explicitly tied to measurable performance targets

Insights

Corporate Governance Expert

TL;DR: Standard executive equity grants with multi-year vesting; aligns executive incentives with shareholder interests but dilutive over time.

The filing documents time-based restricted stock unit awards to a senior executive, which is a common long-term incentive. The awards vest over four years at 25% annually, encouraging retention and alignment with company performance. The grants are reported as direct holdings and have a $0 conversion price because RSUs convert into shares rather than being purchased. From a governance perspective, the structure is routine; materiality depends on the executive's overall holdings and total outstanding shares, which are not disclosed in this form.

Executive Compensation Analyst

TL;DR: Time-based RSU grants consistent with market practice; non-performance-based awards provide retention but lack explicit performance linkage.

The awards total 7,307 RSUs and vest 25% per year over four years. As RSUs, they deliver value only if the recipient remains employed and, upon settlement, dilute existing shareholders. The Form 4 does not show performance conditions or service-only exceptions beyond the stated vesting schedule. Without additional context on target pay levels or total dilution, this appears to be a routine retention award rather than a performance-contingent incentive.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehta Rajat

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DR

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GBL Commercial Operations

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	09/05/2025		A		1,827		(2)	(2)	Bio-Rad A Common Stock	1,827	$0	1,827	D
Restricted Stock Units	$0(1)	09/05/2025		A		5,480		(3)	(3)	Bio-Rad A Common Stock	5,480	$0	5,480	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

2. On September 5, 2025, the reporting person was granted 1,827 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

3. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ Rajat Mehta	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rajat Mehta report on the Form 4 for BIO?

He reported grants of 1,827 RSUs and 5,480 RSUs on 09/05/2025, which are rights to receive Bio-Rad Class A common stock.

When do the restricted stock units granted to Rajat Mehta vest?

They vest over four years at 25% per year, with the 1,827-RSU award vesting in four equal annual installments beginning on the first anniversary of the grant date.

How many total RSUs were granted to the reporting person?

A total of 7,307 RSUs were granted (1,827 plus 5,480).

Are the RSUs held directly or indirectly according to the Form 4?

The Form 4 reports the RSUs as direct ownership (Direct (D) listed for both awards).

What price is reported for these RSUs on the Form 4?

The reported price is $0, reflecting that RSUs are contingent awards converting into shares rather than purchased instruments.